These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 19565360)

  • 1. Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases.
    Emi Aikawa N; de Carvalho JF; Artur Almeida Silva C; Bonfá E
    Clin Rev Allergy Immunol; 2010 Apr; 38(2-3):82-9. PubMed ID: 19565360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis.
    Garcês S; Demengeot J; Benito-Garcia E
    Ann Rheum Dis; 2013 Dec; 72(12):1947-55. PubMed ID: 23223420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
    Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
    Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
    Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
    Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis.
    Thomas SS; Borazan N; Barroso N; Duan L; Taroumian S; Kretzmann B; Bardales R; Elashoff D; Vangala S; Furst DE
    BioDrugs; 2015 Aug; 29(4):241-58. PubMed ID: 26280210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Third generation anti-cyclic citrullinated peptide antibodies do not predict anti-TNF-alpha treatment response in rheumatoid arthritis.
    Dejaco C; Duftner C; Klotz W; Schirmer M; Herold M
    Rheumatol Int; 2010 Feb; 30(4):451-4. PubMed ID: 19506882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
    García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC
    Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O; Caspi D; Reitblatt T; Charboneau D; Rubins JB
    Semin Arthritis Rheum; 2004 Feb; 33(4):283-8. PubMed ID: 14978666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and autoimmunity during anti-TNF therapy.
    Atzeni F; Talotta R; Salaffi F; Cassinotti A; Varisco V; Battellino M; Ardizzone S; Pace F; Sarzi-Puttini P
    Autoimmun Rev; 2013 May; 12(7):703-8. PubMed ID: 23207283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis.
    Moreland LW
    Pharmacoeconomics; 2004; 22(2 Suppl 1):39-53. PubMed ID: 15157003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
    Rudwaleit M; Van den Bosch F; Kron M; Kary S; Kupper H
    Arthritis Res Ther; 2010; 12(3):R117. PubMed ID: 20553600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?
    Joyau C; Veyrac G; Dixneuf V; Jolliet P
    Clin Exp Rheumatol; 2012; 30(5):700-6. PubMed ID: 22935567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Value of anti-TNF-alpha molecules in inflammatory and infectious diseases].
    Fautrel B; Cherin P
    Rev Med Interne; 2000 Oct; 21(10):872-88. PubMed ID: 11075396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New drugs and treatment strategies for rheumatoid arthritis].
    Fantini F
    Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
    Lanfant-Weybel K; Lequerré T; Vittecoq O
    Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of Infliximab Among Patients With Behçet Syndrome: A Controlled Study.
    Esatoglu SN; Akkoc-Mustafayev FN; Ozguler Y; Ozbakır F; Nohut OK; Cevirgen D; Hamuryudan V; Hatemi I; Celik AF; Yazici H; Hatemi G
    Front Immunol; 2020; 11():618973. PubMed ID: 33414791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.